Unexpected Durable Complete Response With Anti–PD-L1 Blockade in Metastatic Undifferentiated Pleomorphic Sarcoma: A Case Report With Host and Tumor Biomarker Analysis
David Pesántez(Hospital Clínic de Barcelona), Javier Garciá Corbacho(Breast Cancer Research Foundation), Fara Brasó‐Maristany(Hospital Clínic de Barcelona), Iván Victoria(Hospital Clínic de Barcelona), Patricia Galván(Vall d'Hebron Institute of Oncology), Manel Juan(Hospital Sant Joan de Déu Barcelona), Marianna Sirico(Istituti Ospitalieri di Cremona), Esther Sanfeliu(Hospital Clínic de Barcelona), Laura Angelats(Hospital Clínic de Barcelona), Alberto Indacochea(Hospital General de Granollers), Aleix Prat(Hospital Clínic de Barcelona), Francesco Schettini(Breast Cancer Research Foundation), Cristina Teixidó(Hospital Clínic de Barcelona), Azucena E. González-Navarro(Hospital Clínic de Barcelona), Pedro Jares(Hospital Clínic de Barcelona)
Cited by 2
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
|Nature|2011|1.5k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k